×
About 1,533 results

ALLMedicine™ Ataxia Telangiectasia Center

Research & Reviews  594 results

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy i...
https://doi.org/10.1136/jitc-2020-001758
Journal for Immunotherapy of Cancer; Wang Z, Zhang X et. al.

Jul 25th, 2021 - The efficacy of docetaxel-based chemotherapy is limited by the development of drug resistance. Recent studies demonstrated the efficacy of anti-programmed death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapies in metastatic prostate...

Targeting the replication stress response through synthetic lethal strategies in cancer...
https://doi.org/10.1016/j.trecan.2021.06.002
Trends in Cancer; Ngoi NYL, Pham MM et. al.

Jul 4th, 2021 - The replication stress response (RSR) involves a downstream kinase cascade comprising ataxia telangiectasia-mutated (ATM), ATM and rad3-related (ATR), checkpoint kinases 1 and 2 (CHK1/2), and WEE1-like protein kinase (WEE1), which cooperate to arr...

ATR regulates neuronal activity by modulating presynaptic firing.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249387
Nature Communications; Kirtay M, Sell J et. al.

Jul 3rd, 2021 - Ataxia Telangiectasia and Rad3-related (ATR) protein, as a key DNA damage response (DDR) regulator, plays an essential function in response to replication stress and controls cell viability. Hypomorphic mutations of ATR cause the human ATR-Seckel ...

Gene expression analysis in EBV-infected ataxia-telangiectasia cell lines by RNA-sequen...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237493
Orphanet Journal of Rare Diseases; Tatfi M, Perthame E et. al.

Jun 30th, 2021 - Epstein-Barr virus (EBV) targets B-cells where it establishes a latent infection. EBV can transform B-cells in vitro and is recognized as an oncogenic virus, especially in the setting of immune compromise. Indeed, immunodeficient patients may fail...

SETD2-mediated H3K14 trimethylation promotes ATR activation and stalled replication for...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201831
Proceedings of the National Academy of Sciences of the Un... Zhu Q, Yang Q et. al.

Jun 3rd, 2021 - Ataxia telangiectasia and Rad3 related (ATR) activation after replication stress involves a cascade of reactions, including replication protein A (RPA) complex loading onto single-stranded DNA and ATR activator loading onto chromatin. The contribu...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  8 results

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02565901

Apr 14th, 2020 - PRIMARY OBJECTIVES: I. To define the recommended phase 2 dose (RP2D) of sirolimus combined with docetaxel and carboplatin in the treatment of metastatic castration resistant prostate cancer (CRPC). (Phase I) II. To assess the effectiveness of siro...

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
https://clinicaltrials.gov/ct2/show/NCT00455403

Mar 25th, 2020 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
https://clinicaltrials.gov/ct2/show/NCT00455325

Feb 17th, 2020 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
https://clinicaltrials.gov/ct2/show/NCT02598895

Jun 28th, 2019 - PRIMARY OBJECTIVES: I. To assess rate of 50% prostate-specific antigen (PSA) decline to docetaxel and carboplatin. SECONDARY OBJECTIVES: I. To assess PSA response duration to docetaxel and carboplatin. (Phase 2) II. To assess response of measurabl...

Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia
https://clinicaltrials.gov/ct2/show/NCT03357978

Nov 30th, 2017 - Ataxia teleangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infecti...

see more →

News  7 results

Drug Duo Targeting ATR Enzyme Shrinks Small Cell Lung Cancer Tumors
https://www.medscape.com/viewarticle/949638

Apr 21st, 2021 - NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-con...

Irinotecan shows promise for triple-negative breast cancer
https://www.mdedge.com/hematology-oncology/article/217772/breast-cancer/irinotecan-shows-promise-triple-negative-breast?channel=39313
Caleb Rans

Feb 24th, 2020 - The topoisomerase I (TOP1) inhibitor irinotecan could be effective in treating triple-negative breast cancer (TNBC), according to results from a preclinical study published in Science Translational Medicine. Florence Coussy, MD, PhD, of Institut C.

Pancreatic Ductal Carcinoma: Slow Progress for a Hard-to-Treat Cancer
https://www.onclive.com/publications/oncology-live/2018/vol-19-no-2/pancreatic-ductal-carcinoma-slow-progress-for-a-hardtotreat-cancer

Jan 17th, 2018 - Johanna C. Bendell, MD The incidence of pancreas cancer continues to rise in many countries.1 In 2017, an estimated 53,600 cases were diagnosed in the United States, representing an approximately 45% increase over the past decade.2,3 Pancreatic du...

AT Children’s Project Advisors Elected to National Academy of Sciences
https://www.mdedge.com/neurology/article/116228/rare-diseases/childrens-project-advisors-elected-national-academy-sciences

Oct 1st, 2016 - Longtime scientific advisors to the AT (Ataxia Telangiectasia) Children’s Project Nathaniel Heintz, PhD, and Michael Kastan, MD, PhD, have been elected to the National Academy of Sciences.

Olaparib + paclitaxel for metastatic gastric cancer
https://www.mdedge.com/hematology-oncology/article/101954/gastroenterology/olaparib-paclitaxel-metastatic-gastric-cancer
Mary Ann Moon

Aug 17th, 2015 - Adding olaparib to second-line paclitaxel therapy for recurrent or metastatic gastric adenocarcinoma improved overall survival but not progression-free survival in a phase II clinical trial, investigators reported online Aug. 17 in Journal of Clin.

see more →

Patient Education  3 results see all →